1. Midline Glioma in Adults: Clinicopathological, Genetic, and Epigenetic Analysis
- Author
-
Masani Nonaka, Mikiko Aoki, Makoto Hamasaki, Kazuki Nabeshima, Toshiyuki Enomoto, Hiroshi Abe, and Tooru Inoue
- Subjects
Adult ,Male ,medicine.medical_specialty ,Poor prognosis ,Jumonji Domain-Containing Histone Demethylases ,Adolescent ,H3K27me3 ,Malignancy ,Gastroenterology ,030218 nuclear medicine & medical imaging ,Epigenesis, Genetic ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,H3K27M ,Glioma ,Internal medicine ,medicine ,Humans ,Enhancer of Zeste Homolog 2 Protein ,EZH2 ,Young adult ,Grading (tumors) ,Aged ,Aged, 80 and over ,business.industry ,Brain Neoplasms ,Genes, p16 ,Epigenetic Analysis ,Age Factors ,Middle Aged ,medicine.disease ,diffuse midline glioma ,Survival Rate ,Purine-Nucleoside Phosphorylase ,Surgery ,Original Article ,Female ,Neurology (clinical) ,business ,030217 neurology & neurosurgery ,Immunostaining - Abstract
The histone H3K27M-mutant diffuse midline glioma is often seen in children and has a very poor prognosis regardless of its histological grade. Although it can occur in adults, few studies on adult cases have been reported. We examined adult midline glioma cases for their histological grade, presence of H3K27M mutation, and expression of related factors-enhancer of zeste homolog 2 (EZH2), H3K27me3, p16, and methylthioadenosine phosphorylase. These tumor characteristics were also evaluated for their prognostic value in adult midline glioma. High histological grade, H3K27M-mutant, high EZH2 expression, and high H3K27me3 expression was detected in 12/23 (53%), 11/23 (48%), 9/23 (39%), and 12/23 (52%) cases, respectively. Histological grade and prognosis were significantly correlated (P
- Published
- 2020